301130.SZ
西点药业
SZSE · Healthcare · C 制造业 · CN
CNY 33.09
+5.45%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
37.9x
Market Cap
CNY 2.53B
MomentumView details →
1D Return
+5.45%
YTD Return
−4.70%
RSI (14)
44.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
37.9x
Market Cap
CNY 2.53B
RSI (14)
44.6
MomentumView details →
1D Return
+5.45%
YTD Return
−4.70%
Similar companies
Latest newsMore news →
Xidian Pharmaceutical received a drug supplementary application approval notice from China's National Medical Products Administration for potassium chloride granules, approving the transfer of the marketing authorization holder from Suzhou Langke Biotechnology to Xidian.2d agoXidian Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders fell 64.21% year-on-year to 8.9272 million yuan, with revenue down 20.95% to 101 million yuan.10d agoXidian Pharmaceutical announced that its registration application for Potassium Chloride Granules was accepted by China's National Medical Products Administration (NMPA).16d ago